| Literature DB >> 17119115 |
Yazan Alsayed1, Hai Ngo, Judith Runnels, Xavier Leleu, Ujjal K Singha, Costas M Pitsillides, Joel A Spencer, Teresa Kimlinger, Joanna M Ghobrial, Xiaoying Jia, Ganwei Lu, Michael Timm, Ashok Kumar, Daniel Côté, Israel Veilleux, Karen E Hedin, G David Roodman, Thomas E Witzig, Andrew L Kung, Teru Hideshima, Kenneth C Anderson, Charles P Lin, Irene M Ghobrial.
Abstract
The mechanisms by which multiple myeloma (MM) cells migrate and home to the bone marrow are not well understood. In this study, we sought to determine the effect of the chemokine SDF-1 (CXCL12) and its receptor CXCR4 on the migration and homing of MM cells. We demonstrated that CXCR4 is differentially expressed at high levels in the peripheral blood and is down-regulated in the bone marrow in response to high levels of SDF-1. SDF-1 induced motility, internalization, and cytoskeletal rearrangement in MM cells evidenced by confocal microscopy. The specific CXCR4 inhibitor AMD3100 and the anti-CXCR4 antibody MAB171 inhibited the migration of MM cells in vitro. CXCR4 knockdown experiments demonstrated that SDF-1-dependent migration was regulated by the P13K and ERK/ MAPK pathways but not by p38 MAPK. In addition, we demonstrated that AMD3100 inhibited the homing of MM cells to the bone marrow niches using in vivo flow cytometry, in vivo confocal microscopy, and whole body bioluminescence imaging. This study, therefore, demonstrates that SDF-1/CXCR4 is a critical regulator of MM homing and that it provides the framework for inhibitors of this pathway to be used in future clinical trials to abrogate MM trafficking.Entities:
Mesh:
Substances:
Year: 2007 PMID: 17119115 PMCID: PMC1852222 DOI: 10.1182/blood-2006-07-035857
Source DB: PubMed Journal: Blood ISSN: 0006-4971 Impact factor: 22.113